Acino, a Swiss pharmaceutical company headquartered in Zurich, and Egypt-based MultiCare for Pharmaceutical Industries have just announced a strategic partnership that aims to enhance patient access to high-quality medicines across the country.
The agreement covers the marketing and distribution of products in new treatments, including diabetes, and hypercholesterolemia, in addition to the existing therapeutic area of gastroenterology in Egypt.
The partnership was formalized at a signing ceremony attended by Andrew Bird, Acino’s Head of Region, Middle East, Turkey, and Africa; Ahmed Serag, Acino’s Country Manager, Egypt; and Ossama Anter Abo Arab, Chairman of MultiCare.
Senior Acino leaders, speaking at the signing, reiterated the company’s efforts to leverage strategic opportunities in the Egyptian pharmaceutical market, bolstering its position as a regional export hub and reinforcing the country’s local manufacturing strategy.
General Manager for the Middle East, Turkey, and Africa for Acino, Andrew Bird, commented on the agreement, saying: Acino is committed to advancing the development of healthcare across Egypt and the wider Middle Eastern region by accelerating access to high-quality medicines that patients and governments can rely on.
He emphasized: Through our partnership with MultiCare, we ensure that Egypt’s enhancements of patient services, medical standards, and treatment outcomes can continue. This collaboration is a vital step as part of our efforts to continue to expand in the region and remain patient oriented across the entire value chain.
Notably, Acino continues to invest in Egypt and has implemented an extensive growth and expansion strategy that will add value to a healthcare sector that is currently undergoing immense transformation.
